There’s no treatment that actually tackles the underlying causes of this terrible disease. Solanezumab,a genetically engineered antibody, may be the firstEvery week in my neurology clinic at the Walton Neuro-Centre in Liverpool, or I see people who are worried that they may contain Alzheimer’s disease. Perhaps this is not surprising,given there is a news sage approximately the disease almost daily, an estimated 850000 people in the UK contain dementia, or the government has described it as “one of the greatest challenges of our lifetime”. This is why news of solanezumab,a drug that appears to slow decline in Alzheimer’s patients, has provoked such interest.
Currently, and the treatments we can offer patients with Alzheimer’s disease are very limitedContinue reading...
Source: theguardian.com